• Image of Gleevec medication

    • IMATINIB MESYLATE (Generic for GLEEVEC)

    • QTY 30
    • 400 MG
    • Tablet

IMATINIB (i MAT in ib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat certain leukemias, myelodysplastic syndromes, and other cancers. It is also used to treat specific digestive tract tumors called GISTs.

IMATINIB MESYLATE (Generic for GLEEVEC) Lifestyle Interactions

  • Imatinib Mesylate 400mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not take Imatinib, STI-571 with grapefruit or grapefruit juice. Taking Imatinib with grapefruit or grapefruit juice may increase side effects of Imatinib. If you accidentally take Imatinib with grapefruit or grapefruit juice, immediately tell your doctor about any unusual effects.
    • Notes for Professionals: Any agent that inhibits cytochrome P450 CYP 3A4, such as grapefruit juice, may decrease the metabolism of imatinib and increase imatinib concentrations leading to an increased incidence of adverse reactions. Monitor patient closely.

  • Imatinib Mesylate 400mg, Oral tablet

    • Interaction: Marijuana
    • Severity: Moderate
    • Notes for Consumers: The effects of marijuana may be increased and side effects may get worse if it is combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.
    • Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with imatinib, STI-571. Imatinib is an inhibitor of CYP2C9 and CYP3A4, two isoenzymes responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with imatinib the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.